HB-172: United States Anti-Doping Agency Reauthorization Act of 2021
Sponsored by: Rep. Bill Johnson
Received In The Senate And Read Twice And Referred To The Committee On Commerce, Science, And Transportation. on 04/15/2021
COVID–19 Vaccine Awareness Support Act of 2020 [HB-8966]
Requires the Centers for Disease Control and Prevention to award grants to state, tribal, territorial, and local health departments or nonprofits to disseminate information about COVID-19 (i.e., coronavirus disease 2019), including regarding the safety and efficacy of vaccines.
HB-8966: COVID–19 Vaccine Awareness Support Act of 2020
Sponsored by: Rep. Scott Peters
Introduced In House on 12/14/2020
STAAR Act Strategies To Address Antibiotic Resistance Act [S.2304]
Expands various initiatives to address antibiotic resistance. The bill reestablishes the interagency Antimicrobial Resistance Task Force to coordinate and develop efforts addressing antibiotic resistance. The Department of Health and Human Services must encourage health care facilities to implement antimicrobial stewardship programs to evaluate and improve the use of antimicrobial drugs. The bill also requires the Centers for Disease Control and Prevention (CDC) to use the National Healthcare Safety Network to collect and report data about the usage
(continued...)
S.2304: STAAR Act Strategies To Address Antibiotic Resistance Act
Sponsored by: Sen. Sherrod Brown
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 07/29/2019
COVID–19 Vaccine Awareness Support Act of 2020 [S.4958]
Requires the Centers for Disease Control and Prevention to award grants to state, tribal, territorial, and local health departments or nonprofits to disseminate information about COVID-19 (i.e., coronavirus disease 2019), including regarding the safety and efficacy of vaccines.
S.4958: COVID–19 Vaccine Awareness Support Act of 2020
Sponsored by: Sen. Rob Portman
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 12/03/2020
FDA Accountability for Public Safety Act [S.954]
FDA Accountability for Public Safety Act This bill requires the Commissioner of Food and Drugs to ensure that an advisory committee of the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) evaluates each new drug application for an opioid (a drug with effects similar to opium, such as morphine) and issues a recommendation regarding approval of the drug. If the decision to approve the drug is inconsistent with the committee's recommendation, the Commissioner must make the final decision on approval. If the committee
(continued...)
S.954: FDA Accountability for Public Safety Act
Sponsored by: Sen. Angus King
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 04/15/2015
Drug Free Commercial Driver Act of 2015 [S.806]
Drug Free Commercial Driver Act of 2015 (Sec. 2) This bill revises regulations that require motor carriers to conduct preemployment, reasonable suspicion, random, and post-accident testing of commercial motor vehicle operators for controlled substances or alcohol. Motor carriers may use hair testing as an acceptable alternative to urinalysis for detecting use of controlled substances by individuals, but only for preemployment testing and random testing. The Department of Transportation shall develop requirements for laboratories and testing procedures
(continued...)
S.806: Drug Free Commercial Driver Act of 2015
Sponsored by: Sen. Joe Manchin
Committee On Commerce, Science, And Transportation. Reported By Senator Thune Under Authority Of The Order Of The Senate Of 03/17/2016 With An Amendment In The Nature Of A Substitute. With Written Report No. 114-232. on 03/28/2016
Increasing the Safety of Prescription Drug Use Act of 2015 [S.636]
Increasing the Safety of Prescription Drug Use Act of 2015 This bill amends the Public Health Service Act to revise, update, and expand state controlled substance monitoring programs, which ensure that prescription history information is accessible for investigations into drug diversion and errant prescribing and dispensing practices. A state's controlled substance monitoring program database must be interoperable with other states' databases and electronic health records, and must provide up-to-date patient information to practitioners. Practitioners
(continued...)
S.636: Increasing the Safety of Prescription Drug Use Act of 2015
Sponsored by: Sen. Tom Udall
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 03/03/2015
Preventing Antibiotic Resistance Act of 2015 [S.621]
Preventing Antibiotic Resistance Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to refuse a new animal drug application if the drug is a medically important antimicrobial (used to treat humans) and the applicant fails to demonstrate that the drug meets specified criteria for use in animals, including that: (1) the drug is effective, (2) the drug is targeted to animals at risk of developing a specific bacterial disease, (3) the drug has a defined duration of therapy, and (4)
(continued...)
S.621: Preventing Antibiotic Resistance Act of 2015
Sponsored by: Sen. Jack Reed
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. (sponsor Introductory Remarks On Measure: Cr S1218-1219) on 03/02/2015
S.524: Co-Prescribing to Reduce Overdoses Act of 2016 Comprehensive Opioid Abuse Reduction Act of 2016 Examining Opioid Treatment Infrastructure Act of 2016 Good Samaritan Assessment Act of 2016 Improving Treatment for Pregnant and Postpartum Women Act of 2016 Infant Plan of Safe Care Improvement Act John Thomas Decker Act of 2016 Kingpin Designation Improvement Act of 2016 Lali's Law National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 Nurturing And Supporting Healthy Babies Act or the NAS Healthy Babies Act Opioid Program Evaluation Act or the OPEN Act Opioid Review Modernization Act of 2016 Opioid Use Disorder Treatment Expansion and Modernization Act Promoting Responsible Opioid Management and Incorporating Scientific Expertise Act or the Jason Simcakoski PROMISE Act Reducing Unused Medications Act of 2016 Veteran Emergency Medical Technician Support Act of 2016 Short Titles - Senate Short Titles as Passed Senate: Comprehensive Addiction and Recovery Act of 2016
Sponsored by: Sen. Susan Collins
Signed By President. on 07/22/2016
You have voted S.524: Co-Prescribing to Reduce Overdoses Act of 2016 Comprehensive Opioid Abuse Reduction Act of 2016 Examining Opioid Treatment Infrastructure Act of 2016 Good Samaritan Assessment Act of 2016 Improving Treatment for Pregnant and Postpartum Women Act of 2016 Infant Plan of Safe Care Improvement Act John Thomas Decker Act of 2016 Kingpin Designation Improvement Act of 2016 Lali's Law National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 Nurturing And Supporting Healthy Babies Act or the NAS Healthy Babies Act Opioid Program Evaluation Act or the OPEN Act Opioid Review Modernization Act of 2016 Opioid Use Disorder Treatment Expansion and Modernization Act Promoting Responsible Opioid Management and Incorporating Scientific Expertise Act or the Jason Simcakoski PROMISE Act Reducing Unused Medications Act of 2016 Veteran Emergency Medical Technician Support Act of 2016 Short Titles - Senate Short Titles as Passed Senate: Comprehensive Addiction and Recovery Act of 2016.
Improving Regulatory Transparency for New Medical Therapies Act [S.481]
Improving Regulatory Transparency for New Medical Therapies Act (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to delay the effective date of approval of a drug, biological product, or animal drug for which the Food and Drug Administration (FDA) recommends controls under the Controlled Substances Act until the Department of Justice (DOJ) issues a final interim rule for the drug. This delay also applies to conditional approval and indexing of animal drugs. This bill amends the Controlled Substances
(continued...)
S.481: Improving Regulatory Transparency for New Medical Therapies Act
Sponsored by: Sen. Sheldon Whitehouse
Committee On Health, Education, Labor, And Pensions. Reported By Senator Alexander With An Amendment In The Nature Of A Substitute. Without Written Report. on 10/01/2015
Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015 [S.441]
Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015 Amends the Federal Food, Drug, and Cosmetic Act to exempt traditional large and premium cigars from regulation by the Food and Drug Administration (FDA) and from user fees assessed on tobacco products by the FDA.
S.441: Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Sponsored by: Sen. Robert Casey
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 02/10/2015
Carl's Law [S.3298]
Carl's Law This bill amends the Federal Food, Drug, and Cosmetic Act to require the label of a drug containing an opioid to prominently state that the drug contains an opioid and addiction to the drug is possible. (Opioids are drugs with effects similar to opium, such as certain pain medications.)
S.3298: Carl's Law
Sponsored by: Sen. Jeanne Shaheen
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 09/07/2016
Medical Innovation Act of 2015 [S.320]
Medical Innovation Act of 2015 This bill amends the Public Health Service Act to require certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a settlement agreement in the previous five years with a federal agency regarding specified violations must pay 1% of its net income to the Department of Health and Human Services (HHS) for each of its covered
(continued...)
S.320: Medical Innovation Act of 2015
Sponsored by: Sen. Elizabeth Warren
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. (sponsor Introductory Remarks On Measure: Cr S657-658) on 01/29/2015
PRICED Act Price Relief, Innovation, and Competition for Essential Drugs Act [S.3094]
PRICED Act Price Relief, Innovation, and Competition for Essential Drugs Act This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period. This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
S.3094: PRICED Act Price Relief, Innovation, and Competition for Essential Drugs Act
Sponsored by: Sen. John McCain
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 06/23/2016